Clinical Trial Update: A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

This document notes that SHR-A2102 is being evaluated in a Phase 2 trial in combination with other anti-tumor therapies for resectable non-small cell lung cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• SHR-A2102

Snippet

Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: RECRUITING